SCHEMBL4880472

SCHEMBL4880472

COc1cccc(C2(C(=O)OS(N)(=O)=O)CCC(=O)CC2)c1

nearest known ligand 0.42

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
STS P08842 2/20 0.42
ADAM17 P78536 1/20 0.40
PDE4A P27815 1/20 0.39
PDE4B Q07343 1/20 0.39
PDE4C Q08493 1/20 0.39
PDE4D Q08499 1/20 0.39
KDM1A O60341 1/20 0.39
ALDH1A1 P00352 1/20 0.39
CA12 O43570 1/20 0.39
CA1 P00915 1/20 0.39
CA2 P00918 1/20 0.39
CA7 P43166 1/20 0.39
CA9 Q16790 1/20 0.39
CA14 Q9ULX7 1/20 0.39
ELOVL1 Q9BW60 1/20 0.39
SIGMAR1 Q99720 2/20 0.38
HCAR2 Q8TDS4 1/20 0.38
KCNA3 P22001 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4876849 0.85 ADAM17 (0.50) ADAM17KDM1AALDH1A1ELOVL1SIGMAR1
SCHEMBL4878265 0.85 ALDH1A1 (0.43) STSADAM17KDM1AALDH1A1CA12
SCHEMBL4880129 0.84 SIGMAR1 (0.41) STSALDH1A1SIGMAR1
SCHEMBL4876712 0.84 OPRD1 (0.46) STSALDH1A1CA12CA1CA2
SCHEMBL11865726 0.82 PDE4A (0.55) ADAM17PDE4APDE4BPDE4CPDE4D
SCHEMBL4880541 0.82 SOAT1 (0.48) ALDH1A1CA12CA1CA2CA9
SCHEMBL4880364 0.81 HDAC4 (0.41) STSADAM17KDM1AALDH1A1
SCHEMBL4877607 0.81 SIGMAR1 (0.42) STSADAM17KDM1AALDH1A1CA12
SCHEMBL4878231 0.81 HCAR2 (0.46) ADAM17KDM1AALDH1A1SIGMAR1HCAR2
SCHEMBL4876701 0.80 ALDH1A1 (0.50) ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080096922-A1 Novel Sulfonamide derivative DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2008-04-24 US disclosed
EP-1736467-A1 NOVEL SULFONAMIDE DERIVATIVE Dainippon Sumitomo Pharma Co., Ltd. (JP) 2006-12-27 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080096922-A1 Novel Sulfonamide derivative NR4A1, NR4A2, NR4A3 STS 68/4885ADAM17 4084/4885PDE4A 1003/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.